Compare Diamondback Energy Inc (FANG) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Diamondback Energy Inc trades at $198 (market cap $55.49B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Diamondback Energy Inc is far larger — about 5.4× Globus Medical Inc. Class A Common Stock's market cap, and Diamondback Energy Inc pays a 2.22% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 70 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FANG | GMED | |
|---|---|---|
Market Cap | $55.49B | $10.25B |
Volume | 2,752,760 | 1,108,124 |
Sector | Energy | Health |
52-Week High | $213.69 | $96.82 |
52-Week Low | $137.29 | $58.33 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $67.65B | $9.76B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $197.51, up 1.23% with strong analyst support (90.57% buy rating) and a $232.54 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, while cash flow from operations improved to $8.76B in 2025. The stock shows bullish technical signals with support at $194 and resistance at $200, though RSI levels indicate potential overbought conditions.
FANG offers growth potential with rising revenue and operational efficiency, but faces risks from oil price volatility and declining profit margins. Institutional buying and positive Permian Basin developments support upside, while insider selling and competitive pressures warrant caution for investors seeking energy exposure.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
